Document is current
Any future updates will be listed below
-
Authors
Lam, Casey
Lanchoney, Olivia
Maddipatla, Vishnu
Markosyan, Nune
Joshi, Nikhil
Hu, Xiaowen
Ray Fofana, Courtney
Zeng, Shan
DeMatteo, Ronald P.
Vonderheide, Robert H.
Zhang, Jennifer Q.
-
Funding
Funding for this research was provided by:
Breast Cancer Research Foundation (BCRF-24-167)
Parker Institute for Cancer Immunotherapy
National Cancer Institute (P30CA016520-46)
Susan G. Komen (SAC232145)
University of Pennsylvania
- License Information
-
More Information
Article History
Received: 4 June 2025
Accepted: 31 December 2025
First Online: 13 January 2026
Competing interests
: Dr. Vonderheide has received consulting fees from BMS, EMD Serono, Grey Wolf Therapeutics and Crossbow Therapeutics, research funding from Revolution Medicines, is an inventor on patents relating to cancer cellular immunotherapy, cancer vaccines, and KRAS immune epitopes, and receives royalties from Children’s Hospital Boston for a licensed research-only monoclonal antibody, but declares no non-financial competing interests. All other authors declare no financial or non-financial competing interests.
